Author:
Febvey-Combes Olivia,Guitton Jérôme,Marec-Berard Perrine,Faure-Conter Cécile,Blanc Ellen,Chabaud Sylvie,Conjard-Duplany Agnès,Schell Matthias,Derain Dubourg Laurence
Abstract
Abstract
Background
Ifosfamide is a major anti-cancer drug in children with well-known renal toxicity. Understanding the mechanisms underlying this toxicity could help identify children at increased risk of toxicity.
Methods
The IFOS01 study included children undergoing ifosfamide-based chemotherapy for Ewing sarcoma or rhabdomyosarcoma. A fully evaluation of renal function was performed during and after chemotherapy. Proton nuclear magnetic resonance (NMR) and conventional biochemistry were used to detect early signs of ifosfamide-induced tubulopathy. The enzymatic activity of aldehyde dehydrogenase (ALDH) was measured in the peripheral blood lymphocytes as a marker of ifosfamide-derived chloroacetaldehyde detoxification capacity. Plasma and urine concentrations of ifosfamide and dechloroethylated metabolites were quantified.
Results
The 15 participants received a median total ifosfamide dose of 59 g/m2 (range: 24–102), given over a median of 7 cycles (range: 4–14). All children had acute proximal tubular toxicity during chemotherapy that was reversible post-cycle, seen with both conventional assays and NMR. After a median follow-up of 31 months, 8/13 children presented overall chronic toxicity among which 7 had decreased glomerular filtration rate. ALDH enzymatic activity showed high inter- and intra-individual variations across cycles, though overall activity looked lower in children who subsequently developed chronic nephrotoxicity. Concentrations of ifosfamide and metabolites were similar in all children.
Conclusions
Acute renal toxicity was frequent during chemotherapy and did not allow identification of children at risk for long-term toxicity. A role of ALDH in late renal dysfunction is possible so further exploration of its enzymatic activity and polymorphism should be encouraged to improve the understanding of ifosfamide-induced nephrotoxicity.
Funder
Ministère des Affaires Sociales et de la Santé
Société Française de lutte contre les Cancers et les leucémies de l’Enfant et de l’adolescent
Publisher
Springer Science and Business Media LLC
Reference46 articles.
1. Cancer Statistics SEER, Review. 1975–2017, National Cancer Institute. Bethesda, MD. [https://seer.cancer.gov/csr/1975_2017/].
2. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nat Rev Cancer. 2002;2(2):124–32.
3. Ehrhardt MJ, Skinner R, Castellino SM. Renal and hepatic Health after Childhood Cancer. Pediatr Clin North Am. 2020;67(6):1203–17.
4. Skinner R, Pearson AD, English MW, Price L, Wyllie RA, Coulthard MG, Craft AW. Risk factors for ifosfamide nephrotoxicity in children. Lancet. 1996;348(9027):578–80.
5. Rossi R, Ehrich JH. Partial and complete de Toni-Debre-Fanconi syndrome after ifosfamide chemotherapy of childhood malignancy. Eur J Clin Pharmacol. 1993;44(Suppl 1):43–5.